FDA
-
-
-
-
-
-
-
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
-
-
-
-
-
-
-
Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock
-
-
-
-
-
-
-
Zymeworks presents preclinical data on RAS-targeting drug conjugates
-
-
-
-
-
-
-
Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate
-
-
-
-
-
-
-
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
-
-
-
-
-
-
-
Zymeworks names Scott Platshon as acting chief investment officer
-
-
-
-
-
-
-
Zymeworks Announces Participation in Upcoming Investor Conferences
-
334,836 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


